BSH 2017: Are we ready to use minimum residual disease to direct therapy?
Studies show that MM patients who achieve minimal residual disease on treatment have longer PFS and OS than those who do not…
Studies show that MM patients who achieve minimal residual disease on treatment have longer PFS and OS than those who do not…
Dr Andrei Shustov (University of Washington School of Medicine, Seattle, USA) summarises the advances in T-Cell lymphoma therapy at ASH 2016, including long term data in PTCL and ALCL…. read more.
Professor Mohamad Mohty (Paris), Professor Sagar Lonial (Atlanta) and Dr Karthik Ramasamy (Oxford) discuss their highlights from The European School of Haematology Congress on Multiple Myeloma this month. This issue covers the growing… read more.
Consolidation and maintenance therapy for multiple myeloma: is it the new standard? Professor Antonio Palumbo (University of Turin, Italy) and Professor Paul Richardson (Harvard Medical School, Boston,… read more.
Pathophysiology and diagnosis of multiple myeloma bone disease Evangelos Terpos, University of Athens School of Medicine, Greece Osteolytic bone disease is the most common complication of MM and… read more.
Pathophysiology and diagnosis of multiple myeloma bone disease Evangelos Terpos, University of Athens School of Medicine, Greece Osteolytic bone disease is the most common complication of MM and… read more.
Hans Erik Johnsen, Aalborg University Hospital, Denmark. by Maria Dalby: The gene expression profiles of myeloma plasma cells in the normal bone marrow can be used for defining… read more.
Managing multiple myeloma in elderly/frail patients Although multiple myeloma is a disease of old age, elderly patients vary a great deal in terms of fitness and ability… read more.
Preventing clonal evolution in multiple myeloma – evidence from clinical trials by Maria Dalby Professor Roman Hájek from the Czech Republic discussed the clinical implications of clonal evolution… read more.
How monoclonal antibodies will change the treatment of multiple myeloma by Maria Dalby Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France Meletios Dimopoulos, University of Athens School of… read more.
by Bruce Sylvester: Pioglitazone shows efficacy against the progression of nonalcoholic steatohepatitis, or NASH, a chronic liver disease caused by a buildup of fat. Researchers reported this finding… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.